| Literature DB >> 12528803 |
Thomas Schöndorf1, Rainer Neumann, Carolin Benz, Martina Becker, Marion Riffelmann, Uwe-Jochen Göhring, Judith Sartorius, Carl-Heinz Wirsing von König, Martina Breidenbach, Markus M Valter, Markus Hoopmann, Federica Di Nicolantonio, Christian M Kurbacher.
Abstract
The clinical observation of the multidrug resistance (MDR) phenotype is often associated with overexpression of the mdrl gene, in particular with respect to ovarian cancer. However, until now the mdrl-inducing potential of commonly used antineoplastics has been only incompletely explored. We performed short-term cultures of six ovarian cancer cell lines (MZOV4, EF027, SKOV3, OAW42, OTN14, MZOV20) exposed to either blank medium or cisplatin, doxorubicin or paclitaxel at concentrations related to the clinically achievable plasma peak concentration. A highly specific quantitative real-time RT-PCR was used to detect the Mdr1 transcripts. Mdrl mRNA contents were calibrated in relation to coamplified GAPDH mRNA. Mdrl mRNA was detectable in each cell line. In 13 out of 18 assays (72%) the specific anticancer drug being tested induced mdr1 transcription. No decrease in mdr1 mRNA concentration was observed. Our data suggest that mdr1 induction by antineoplastics is one of the reasons for failure of ovarian cancer therapy but may vary individually.Entities:
Mesh:
Substances:
Year: 2003 PMID: 12528803 DOI: 10.1007/978-3-642-19022-3_10
Source DB: PubMed Journal: Recent Results Cancer Res ISSN: 0080-0015